AU6664190A - Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen - Google Patents

Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen

Info

Publication number
AU6664190A
AU6664190A AU66641/90A AU6664190A AU6664190A AU 6664190 A AU6664190 A AU 6664190A AU 66641/90 A AU66641/90 A AU 66641/90A AU 6664190 A AU6664190 A AU 6664190A AU 6664190 A AU6664190 A AU 6664190A
Authority
AU
Australia
Prior art keywords
human
specificity
antibody
tumor cell
cell antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU66641/90A
Other versions
AU634314B2 (en
Inventor
Marc D. Better
Arnold H. Horwitz
Shau-Ping Lei
Randy R. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Xoma Corp
Original Assignee
GREEN CROSS CORP
Green Cross Corp Japan
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GREEN CROSS CORP, Green Cross Corp Japan, Xoma Corp filed Critical GREEN CROSS CORP
Publication of AU6664190A publication Critical patent/AU6664190A/en
Application granted granted Critical
Publication of AU634314B2 publication Critical patent/AU634314B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
AU66641/90A 1989-11-13 1990-11-13 Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen Ceased AU634314B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43501289A 1989-11-13 1989-11-13
US435012 1989-11-13

Publications (2)

Publication Number Publication Date
AU6664190A true AU6664190A (en) 1991-05-23
AU634314B2 AU634314B2 (en) 1993-02-18

Family

ID=23726623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66641/90A Ceased AU634314B2 (en) 1989-11-13 1990-11-13 Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen

Country Status (6)

Country Link
EP (1) EP0457875A4 (en)
JP (1) JPH03206886A (en)
KR (1) KR910009284A (en)
AU (1) AU634314B2 (en)
CA (1) CA2044590A1 (en)
WO (1) WO1991007418A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
WO1997037690A2 (en) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
IT1289608B1 (en) * 1997-02-05 1998-10-15 Angelini Ricerche Spa COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US7033594B2 (en) 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
CA2484640C (en) 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
JP5576007B2 (en) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド Vitamin receptor binding drug delivery conjugates
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20080280937A1 (en) 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
KR20130113543A (en) 2005-08-19 2013-10-15 엔도사이트, 인코포레이티드 Multi-drug ligand conjugates
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
SI2187965T1 (en) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Psma binding ligand-linker conjugates and methods for using
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP2014530360A (en) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA OxMIF as a diagnostic marker
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
EP2919774A4 (en) 2012-11-15 2016-11-09 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
AR125353A1 (en) 2021-04-16 2023-07-12 Novartis Ag RADIOTHERAPEUTIC AGENTS DIRECTED TO THE FOLATE RECEPTOR AND THEIR USE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
IL89489A0 (en) * 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen

Also Published As

Publication number Publication date
AU634314B2 (en) 1993-02-18
KR910009284A (en) 1991-06-28
EP0457875A1 (en) 1991-11-27
EP0457875A4 (en) 1993-03-03
WO1991007418A1 (en) 1991-05-30
CA2044590A1 (en) 1991-05-14
JPH03206886A (en) 1991-09-10

Similar Documents

Publication Publication Date Title
AU6664190A (en) Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
AU1085488A (en) Monoclonal antibodies to a pan-malarial antigen
AU4725485A (en) Monoclonal antibody to a human carcinoma tumor associated antigen
OA09734A (en) Chimeric antibody with specificity to human B cell surface antigen.
GR900100221A (en) Novel monoclonic antibodies against a new antigen relating to human tumours
AU3107289A (en) Chimeric antibodies directed against human carcinoembryonic antigen
AU5141193A (en) Monoclonal antibodies to prostate cells
AU625613B2 (en) Novel chimeric antibodies
ZA884651B (en) Monoclonal antibody specific to hiv antigens
GB8800077D0 (en) Novel chimeric antibodies
ZA887771B (en) Monoclonal antibody specific to a novel epitope of the lfa-1 antigen of human t lymphocytes
AU627591B2 (en) Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
ZA852426B (en) Monoclonal antibody specific for human basal cell surface antigen
AU6663990A (en) Chimeric mouse-human antibodies with specificity to hiv antigens
AU6036690A (en) Human monoclonal antibodies to hiv-1mn gp 120
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
EP0159025A3 (en) Monoclonal antibody specific to human alpha2-plasmin
AU7912887A (en) Monoclonal antibodies to fibrin
AU4450389A (en) Anti-fucosylcermiade monoclonal antibody
AU569816B2 (en) Monoclonal anti-alpha-amylase antibody
AU4407989A (en) Monoclonal antibody specific to a novel mucin-like glycoprotein antigen on human carcinoma cells
AU4070685A (en) Monoclonal antibody specific for human basal cell surfaces
AU3812485A (en) Monoclonal antibody to activated macrophages
AU6609686A (en) Detection of human cancer with a monoclonal antibody specific for antigen 9p650
AU620330B2 (en) Immunodiagnostic assays using chimeric antigens